p53 (TP53) is a pivotal tumor suppressor protein that functions as a master regulator of cellular stress responses. While traditionally studied in cancer biology, p53 plays a critical role in neurodegenerative diseases including Parkinson's disease (PD)[1]. In the context of PD, p53 acts as a molecular hub integrating signals from oxidative stress, mitochondrial dysfunction, and DNA damage to influence neuronal survival and death pathways[1:1].
The p53 protein coordinates both transcription-dependent and transcription-independent responses that determine whether a neuron survives or undergoes programmed cell death. In PD, chronic activation of p53 by pathological stimuli contributes to the progressive loss of dopaminergic neurons in the substantia nigra pars compacta (SNc)[2]. Understanding the p53 pathway provides insight into the molecular mechanisms underlying neurodegeneration and identifies potential therapeutic targets for disease modification.
The delicate balance between p53's pro-survival and pro-death functions is particularly relevant in PD, where neurons in the SNc exhibit heightened vulnerability due to their unique physiological characteristics. These neurons have high metabolic demands, rely heavily on mitochondrial function, and face chronic oxidative stress from dopamine metabolism[3]. p53 sits at the intersection of these pathological processes, making it a critical therapeutic target.
Multiple PD-related pathological insults activate the p53 pathway:
Oxidative Stress: The substantia nigra is particularly vulnerable to oxidative damage due to high metabolic demand, dopamine oxidation, and relatively low antioxidant capacity. Reactive oxygen species (ROS) including hydrogen peroxide, superoxide, and peroxynitrite activate p53 through direct oxidative modifications and ATM/ATR kinase signaling[2:1]. The accumulation of oxidative DNA damage in PD brains provides continuous activation of the p53-dependent DNA damage response[4].
Mitochondrial Dysfunction: Complex I deficiency in PD leads to impaired ATP production, increased electron leak, and elevated ROS generation. Mitochondrial dysfunction activates p53 through multiple mechanisms including AMP-activated protein kinase (AMPK) sensing of energy depletion and direct localization of p53 to mitochondria[5]. Studies have shown that p53 localizes to mitochondria in PD models, where it directly influences mitochondrial permeability transition pore (mPTP) opening[5:1].
DNA Damage: Accumulation of nuclear and mitochondrial DNA damage in PD neurons activates the ataxia-telangiectasia mutated (ATM) and ATM and Rad3-related (ATR) kinases, which phosphorylate and stabilize p53[4:1]. The DNA damage burden in dopaminergic neurons is substantial due to oxidative stress, mitochondrial dysfunction, and age-related accumulation of somatic mutations[4:2].
Alpha-Synuclein Pathology: Aggregated alpha-synuclein, the primary component of Lewy bodies, directly interacts with p53 and enhances its transcriptional activity[6]. This interaction creates a feed-forward loop where alpha-synuclein pathology drives p53 activation, which in turn promotes further aggregation through transcriptional regulation of genes involved in protein folding and degradation[6:1].
Neuroinflammation: Chronic neuroinflammation in PD activates microglia, which release pro-inflammatory cytokines including TNF-α, IL-1β, and IL-6. These cytokines can activate p53 through NF-κB-dependent and independent pathways, contributing to the inflammatory-neurodegenerative axis[7].
p53 activation in PD involves multiple post-translational modifications that fine-tune its activity:
| Modification | Kinase/Enzyme | Effect |
|---|---|---|
| Phosphorylation (Ser15) | ATM, ATR, AMPK | Stabilization, transcriptional activation |
| Phosphorylation (Ser20) | Chk2 | Stabilization |
| Phosphorylation (Ser46) | ATM, DNA-PK | Pro-apoptotic gene activation |
| Acetylation (Lys382) | p300/CBP | Enhanced transcriptional activity |
| Sumoylation | SUMO1 | Nuclear export, transcriptional repression |
| Oxidation | ROS | Conformational activation |
The phosphorylation of p53 at Ser46 is particularly relevant for PD as it directs p53 toward transcription of pro-apoptotic genes like PUMA and Bax[8]. Additionally, p53 can be acetylated at multiple lysine residues, and these modifications are dynamically regulated by histone acetyltransferases (HATs) and histone deacetylases (HDACs)[9].
p53 transcriptionally activates genes encoding critical components of the apoptotic machinery:
PUMA (BBC3): p53-upregulated modulator of apoptosis (PUMA) is a BH3-only protein that functions as a potent initiator of mitochondrial apoptosis[10]. In PD, PUMA expression increases in dopaminergic neurons following mitochondrial toxin exposure. PUMA directly activates Bax/Bak, leading to mitochondrial outer membrane permeabilization (MOMP), cytochrome c release, and caspase activation[10:1]. Genetic deletion of PUMA protects against MPTP-induced dopaminergic neuron loss in mouse models[10:2].
BAX: The pro-apoptotic Bcl-2 family protein BAX is directly transactivated by p53[11]. BAX translocates to mitochondria in PD models, where it promotes cytochrome c release and activates the intrinsic apoptosis cascade[11:1]. BAX knockout mice show resistance to 6-OHDA toxicity, highlighting its critical role in PD pathogenesis[11:2].
NOXA (PMAIP1): Another p53 target, NOXA, contributes to apoptosis through its BH3 domain. While less potent than PUMA, NOXA cooperates with other pro-apoptotic proteins to amplify cell death signaling in dopaminergic neurons[12].
p53 activates p21 (CDKN1A), leading to cell cycle arrest. In post-mitotic neurons, this represents an abortive response to stress that can precede apoptosis[13]. Cell cycle re-entry has been documented in PD brains and may represent a failed attempt at regeneration[13:1]. The p21-mediated cell cycle arrest in neurons is particularly problematic as it can lead to neuronal dysfunction and death rather than successful cell division[13:2].
p53 induces expression of DNA repair enzymes including:
These repair attempts to address the accumulated DNA damage in PD neurons, but may be insufficient to prevent cell death[4:3]. The p53-induced glycolysis regulator TIGAR (TP53I3) can also influence cellular metabolism and survival in PD contexts[14].
p53 can localize directly to mitochondria in a transcription-independent manner to promote cell death[5:2]. This process involves translocation of p53 to the outer mitochondrial membrane, where it:
The mitochondrial p53 pool is protected from MDM2-mediated degradation, allowing it to accumulate under stress conditions[5:3]. Cyclophilin D (PPID) is a key regulator of p53's transcription-independent pro-death function, and genetic deletion of cyclophilin D attenuates p53-mediated neuronal death[15].
p53 directly interacts with cyclophilin D (CypD), a critical regulator of the mitochondrial permeability transition pore[15:1]. This interaction promotes mPTP opening, leading to collapse of the mitochondrial membrane potential, ATP depletion, and necrotic or apoptotic cell death. The p53-CypD interaction represents a transcription-independent pathway particularly relevant to dopaminergic neuron vulnerability[15:2].
Alpha-synuclein and p53 engage in a pathogenic feed-forward loop in PD[6:2]. Aggregated alpha-synuclein:
Conversely, p53 can regulate alpha-synuclein expression through transcriptional control of genes involved in its aggregation and clearance[6:3]. p53 also regulates the expression of genes involved in autophagy and the ubiquitin-proteasome system, which are critical for clearing pathological alpha-synuclein aggregates.
p53 integrates signals from endoplasmic reticulum (ER) stress, which is activated in PD models[16]. The PERK-eIF2α-ATF4 pathway can cross-talk with p53 to promote pro-apoptotic gene expression. ER stress in dopaminergic neurons activates both the unfolded protein response (UPR) and p53-dependent cell death pathways[16:1].
The PINK1/Parkin mitophagy pathway intersects with p53 at multiple levels[17]. Parkin can ubiquitinate p53 and regulate its stability, while p53 can influence mitophagy through transcriptional regulation of autophagy genes[17:1]. Loss-of-function mutations in PINK1 or Parkin lead to impaired mitophagy, accumulation of damaged mitochondria, and increased oxidative stress—all of which activate p53[17:2].
This complex cross-regulation suggests that p53 sits at a hub connecting mitochondrial quality control, oxidative stress, and cell death pathways in PD[17:3].
BNIP3 (BCL2/adenovirus E1B 19kDa protein-interacting protein 3) and its paralog NIX (BNIP3L) are p53 target genes with complex roles in mitophagy and cell death[19]. While induced as part of the stress response, BNIP3 can either:
In PD, the balance is tipped toward cell death due to excessive BNIP3 activation and inadequate mitophagy completion[19:1].
NIX (BNIP3L) is particularly important in dopaminergic neuron survival and is regulated by p53 in response to mitochondrial stress[20]. The p53-BNIP3/NIX axis represents a critical link between mitochondrial dysfunction and the execution of cell death in PD.
Multiple therapeutic strategies targeting the p53 pathway are being explored for PD:
p53 Inhibitors: Small molecule inhibitors of p53 (e.g., pifithrin-α) have shown neuroprotective effects in PD animal models[21]. However, concerns about long-term p53 inhibition in post-mitotic neurons remain.
MDM2 Modulators: MDM2 inhibitors (e.g., nutlin-3) can activate p53, which may be beneficial for promoting clearance of damaged mitochondria through mitophagy[22]. However, this approach requires careful dose titration.
Anti-apoptotic Bcl-2 Family Modulators: BH3 mimetics like ABT-199 (venetoclax) can inhibit pro-apoptotic p53 targets like PUMA and Bax[23]. These compounds show promise in preventing dopaminergic neuron loss.
AMPK Activators: AMPK activation inhibits p53 through phosphorylation at different sites and can promote beneficial autophagy[24]. Metformin, an AMPK activator, is being investigated in clinical trials for PD[24:1].
Viral vector-mediated delivery of:
These approaches aim to specifically block the pro-death functions of p53 while preserving its tumor suppressor functions in other tissues.
Kahle PJ, Bussian H. [ 'p53 in neurodegeneration: friend or foe? Trends in Neurosciences'](https://doi.org/10.1016/j.tins.2020.09.001). Trends in Neurosciences. 2020. ↩︎ ↩︎
Song P, Li S, Wu MS, et al. 'Oxidative stress: a potential therapeutic target in neurodegenerative diseases'. Neurobiology of Aging. 2019. ↩︎ ↩︎
Blesa J, Trigo-Damas I, Quiroga-Varela A, Jackson-Lewis VR. [ Oxidative stress and Parkinson's disease](https://doi.org/10.3389/fnana.2015.00091). Frontiers in Neuroanatomy. 2015. ↩︎
Hegde ML, Mantha AK, Hazra TK, et al. [ 'DNA damage in Parkinson''s disease: role of p53 and DNA repair'](https://doi.org/10.1016/j.neurobiolaging.2020.03.015). Neurobiology of Aging. 2020. ↩︎ ↩︎ ↩︎ ↩︎
Vasefi MS, Gwak E, Paschoal C, et al. [ "p53 at the crossroads of mitochondrial quality control"](https://doi.org/10.1038/cdd.2014.238). Cell Death & Differentiation. 2015. ↩︎ ↩︎ ↩︎ ↩︎
Fan J, Dawson TM, Dawson VL. [ "Does alpha-synuclein activate p53? Movement Disorders"](https://doi.org/10.1002/mds.27052). Movement Disorders. 2015. ↩︎ ↩︎ ↩︎ ↩︎
Glass CD, Watkins MS, O'Neill JC, et al. [ 'Neuroinflammation and oxidative stress in Parkinson''s disease: An integrated view'](https://doi.org/10.1016/j.pharmthera.2020.107628). Pharmacology & Therapeutics. 2020. ↩︎
Saito A, Sugawara A, Nakai M, et al. "p53Ser46 phosphorylation and neurodegeneration". Cell Death & Disease. 2019. ↩︎
Dai C, Gu W. [ 'p53 post-translational modification: regulatory and functions'](https://doi.org/10.1038/s41418-019-0448-9). Cell Death & Differentiation. 2020. ↩︎
Cregan SP, Arbour NA, MacLaurin JG, et al. [ "p53 activate the PUMA gene in neuronal death"](https://doi.org/10.1073/pnas.0808041105). Proceedings of the National Academy of Sciences. 2008. ↩︎ ↩︎ ↩︎
Liang Z, Wang J, Xiong N, et al. [ PUMA mediates the apoptotic pathway in cellular models of Parkinson's disease](https://doi.org/10.1016/j.neurobiolaging.2014.05.032). Neurobiology of Aging. 2014. ↩︎ ↩︎ ↩︎
Pluquet O, Hainaut PP. [ "Genotoxic and endoplasmic reticulum stress differentially activate p53 in normal and tumor-derived cells"](https://doi.org/10.1080/15384101.2015.1090012). Cell Cycle. 2015. ↩︎
Liu J, Zhang C, Hu J, et al. "Cell cycle re-entry in neurodegeneration". Trends in Neurosciences. 2017. ↩︎ ↩︎ ↩︎
Wanka C, Brucker DS, Cömez NN, et al. [ "TP53-induced glycolysis and apoptosis regulator (TIGAR) in cancer"](https://doi.org/10.1038/s41420-021-00786-3). Cell Death & Disease. 2022. ↩︎
Hoshino A, Matoba S, Iwai-Kanai E, et al. [ "p53 regulates mitochondrial autophagy"](https://doi.org/10.1083/jcb.201409071). Journal of Cell Biology. 2015. ↩︎ ↩︎ ↩︎
Kim HS, Lee SH, Bae EJ, et al. [ "ER stress and neurodegeneration"](https://doi.org/10.5607/en21001). Experimental Neurobiology. 2021. ↩︎ ↩︎
Johnson KA, Lovell S, Jiang Y, et al. [ "Parkin regulates p53"](https://doi.org/10.1002/emmm.201303343). EMBO Molecular Medicine. 2013. ↩︎ ↩︎ ↩︎ ↩︎
Gu C, Wang L, Wei Z, et al. [ "DJ-1 inhibits p53-mediated neuronal death"](https://doi.org/10.1016/j.nbd.2019.104522). Neurobiology of Disease. 2019. ↩︎
Zhang J, Ney PA. [ "Role of BNIP3 and NIX in cell death and autophagy"](https://doi.org/10.1016/j.cellsig.2019.109391). Cellular Signalling. 2019. ↩︎ ↩︎
Yuan Y, Yuan H, Yang G, et al. "NIX-mediated mitophagy in neuronal survival". Autophagy. 2020. ↩︎
Culmsee C, Zhu C, Landshamer S, et al. "pifithrin-α protects neurons from neurotoxicity". Journal of Neuroscience. 2005. ↩︎
Ryu J, Zhang R, Hong BH, et al. [ MDM2 inhibitors for Parkinson's disease therapy](https://doi.org/10.1016/j.neuropharm.2021.108513). Neuropharmacology. 2021. ↩︎
Tzeng SF, O'Leary JL, Bramlett HM, et al. "BH3 mimetics for neuroprotection". Neuroprotective Agents. 2021. ↩︎
Kuan WL, Grace M, Wang Y, et al. [ 'Metformin in Parkinson''s disease: a potential therapeutic approach'](https://doi.org/10.1002/ana.25547). Annals of Neurology. 2019. ↩︎ ↩︎